ethyl 4-cyclohexyl-2,4-dioxobutanoate | 893643-33-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: ethyl 4-cyclohexyl-2,4-dioxobutanoate
• CAS: 893643-33-9
• 化学式: C₁₂H₁₈O₄
• 分子量: 226.273
• InChiKey: AENZJLQZKJPTQT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  60.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 4-cyclohexyl-2,4-dioxobutanoate 在 sodium tetrahydroborate 、 四溴化碳 、 盐酸羟胺 、 三乙胺 、 三苯基膦 、 cesium iodide 作用下， 以 甲醇 、 二氯甲烷 、 异丙醇 为溶剂， 生成 N-[(5-cyclohexyl-1,2-oxazol-3-yl)methyl]adamantan-1-amine
  参考文献：
  名称：

  In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses

  摘要：

  Influenza viruses are respiratory pathogens that are responsible for both seasonal influenza epidemics and occasional influenza pandemics. The narrow therapeutic window of oseltamivir, coupled with the emergence of drug resistance, calls for the next-generation of antivirals. With our continuous interest in developing AM2-S31N inhibitors as oral influenza antivirals, we report here the progress of optimizing the in vitro pharmacokinetic (PK) properties of AM2-S31N inhibitors. Several AM2-S31N inhibitors, including compound 10b, were discovered to have potent channel blockage, single to submicromolar antiviral activity, and favorable in vitro PK properties. The antiviral efficacy of compound 10b was also synergistic with oseltamivir carboxylate. Interestingly, binding kinetic studies (K-d, K-on, and K-off) revealed several AM2-S31N inhibitors that have similar K-d values but significantly different K-on and K-off values. Overall, this study identified a potent lead compound (10b) with improved in vitro PK properties that is suitable for the in vivo mouse model studies.

  DOI：

  10.1021/acs.jmedchem.7b01536
• 作为产物：
  描述：

  乙酰基环己烷 、 草酸二乙酯 在 lithium diisopropyl amide 作用下， 生成 ethyl 4-cyclohexyl-2,4-dioxobutanoate
  参考文献：
  名称：

  β-酰胺甲基乙烯基砜作为具有抗α病毒活性的基孔肯雅热nsP2半胱氨酸蛋白酶共价抑制剂的结构活性

  摘要：

  尽管它们对人类健康有广泛的影响，但目前还没有获批的药物来对抗甲病毒感染。杂环 β-氨基甲基乙烯基砜 RA-0002034 （1a） 是一种有效的、不可逆的甲病毒 nsP2 半胱氨酸蛋白酶共价抑制剂，具有广谱抗病毒活性。合成了改变分子三个区域中每个区域的 1a 类似物，以建立抑制基孔肯雅热 （CHIKV） nsP2 蛋白酶和病毒复制的结构-活性关系。乙烯基砜共价弹头对修饰高度敏感。然而，核心五元杂环和芳基取代基的改变具有良好的耐受性。5-（2,5-二甲氧基苯基）吡唑 （1o） 和 4-氰基吡唑 （8d） 类似物表现出 k无效/K 比率 >9000 M–1 s–1。3-芳基恶唑 （10） 被鉴定为五元杂环的等构替代物，它规避了吡唑类抑制剂（如 1a）的分子内环化。开发了一种基于配体的酶活性位点模型，以帮助设计 nsP2 蛋白酶抑制剂作为针对甲病毒的潜在疗法。

  DOI：

  10.1021/acs.jmedchem.4c01346

文献信息

• [EN] PYRAZOLE DERIVATIVES AS S1P1 AGONISTS<br/>[FR] DÉRIVÉS DU PYRAZOLE EN TANT QU'AGONISTES S1P1
  申请人：ALMIRALL SA

  公开号：WO2011144338A1

  公开（公告）日：2011-11-24

  The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by sphingosine-1-phosphate receptors (S1P1) agonists.

  本发明涉及式(I)的化合物，制备此类化合物的方法以及它们在治疗可通过鞘氨醇-1-磷酸受体（S1P1）激动剂改善的病理状况或疾病中的用途。
• New pyrazole derivatives
  申请人：Almirall, S.A.

  公开号：EP2390252A1

  公开（公告）日：2011-11-30

  The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by sphingosine-1-phosphate receptors (S1P1) agonists.

  本发明涉及式(I)的化合物，其制备过程，以及它们在治疗可通过sphingosine-1-phosphate受体（S1P1）激动剂改善的病理状况或疾病中的用途。
• Compounds and methods of use
  申请人：Tango Therapeutics, Inc.

  公开号：US11077101B1

  公开（公告）日：2021-08-03

  Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X1, X2, X3, X4, Y, A, L1, L2, R1, R2, R5, m and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

  根据以下公式（I）提供化合物： 及其药学上可接受的盐，以及其药物组合物；其中X1、X2、X3、X4、Y、A、L1、L2、R1、R2、R5、m和n如本文所定义。本发明的化合物被认为对预防和治疗各种疾病条件有用。
• New pyrazole derivatives as CRAC channel modulators
  申请人：Almirall, S.A.

  公开号：EP2848615A1

  公开（公告）日：2015-03-18

  The present invention relates to compounds of formula (I) which are inhibitors of CRAC channel activity. This invention also relates to pharmaceutical compositions containing them, process for their preparation and their use in therapy.

  本发明涉及一种具有式(I)的化合物，它们是CRAC通道活性的抑制剂。本发明还涉及含有这些化合物的药物组合物、它们的制备过程以及它们在治疗中的应用。
• Novel Inhibitors of Glutaminyl Cyclase
  申请人：Thormann Michael

  公开号：US20090269301A1

  公开（公告）日：2009-10-29

  The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, R 1 represents heteroaryl, -carbocyclyl-heteroaryl, -alkenylheteroaryl or -alkylheteroaryl; R 2 represents hydrogen; halogen; alkenyl; alkynyl; -alkenylaryl; -alkenylheteroaryl; alkyl, which may optionally be substituted by one or more groups selected from halogen, hydroxyl, alkoxy-, -thioalkyl, —C(O)OH and —C(O)O-alkyl; carbocyclyl, which may optionally be substituted by one or more groups selected from alkyl, halogen, hydroxyl, alkoxy-, -thioalkyl, —C(O)OH and —C(O)O-alkyl; -alkylcarbocyclyl; -alkylheterocyclyl; aryl; heteroaryl; heterocyclyl; -alkylaryl; -alkyl(aryl) 2 , -alkylheteroaryl; -aryl-heteroaryl; -heterocyclyl-aryl; -aryl-aryl; -heteroaryl-aryl; -heteroaryl-heteroaryl, and —C(O)R 4 ; R 3 represents halogen; alkyl optionally substituted by one or more groups selected from halogen, hydroxyl, alkoxy, thioalkyl, —C(O)OH and —C(O)O-alkyl; aryl; heteroaryl; —C(O)R 5 ; R 4 and R 5 independently represent alkyl, aryl, heteroaryl, -alkylaryl, -alkylheteroaryl, carbocyclyl, heterocyclyl, -alkylcarbocyclyl and -alkylheterocyclyl, with the proviso that, when R 1 is imidazolyl, -carbocyclyl-imidazolyl, -alkenyl-imidazolyl or -alkyl-imidazolyl, then R 3 may not be —C(O)R 5 .

  本发明涉及式（I）化合物，其组合物和用于疾病治疗的用途。其中，R1代表杂环芳基，-碳环芳基-杂环芳基，-烯基杂环芳基或-烷基杂环芳基；R2代表氢，卤素，烯基，炔基，-烯基芳基，-烯基杂环芳基，烷基，可以选择被一个或多个从卤素，羟基，烷氧基，硫代烷基，-C（O）OH和-C（O）O-烷基中选择的基团取代的烷基，可以选择被一个或多个从烷基，卤素，羟基，烷氧基，硫代烷基，-C（O）OH和-C（O）O-烷基中选择的基团取代的碳环芳基，可以选择被一个或多个从烷基，卤素，羟基，烷氧基，硫代烷基，-C（O）OH和-C（O）O-烷基中选择的基团取代的-烷基碳环芳基，-烷基杂环芳基，芳基，杂环芳基，杂环芳基，-烷基芳基2，-烷基杂环芳基，-芳基杂环芳基，-杂环芳基-芳基，-芳基-芳基，-杂环芳基-芳基，-杂环芳基-杂环芳基和-C（O）R4；R3代表卤素，烷基，可以选择被一个或多个从卤素，羟基，烷氧基，硫代烷基，-C（O）OH和-C（O）O-烷基中选择的基团取代的烷基，芳基，杂环芳基和-C（O）R5；R4和R5独立地代表烷基，芳基，杂环芳基，-烷基芳基，-烷基杂环芳基，碳环芳基，杂环芳基，-烷基碳环芳基和-烷基杂环芳基，但当R1是咪唑基，-碳环芳基-咪唑基，-烯基咪唑基或-烷基咪唑基时，R3不能是-C（O）R5。